HALOZYME THERAPEUTICS, INC. (HALO) Form 8-K — Aug 18, 2026
An 8-K filed August 18, 2026 discloses that Halozyme Therapeutics elected Dannielle Appelhans to its Board of Directors on August 14, 2026. Ms. Appelhans joins the class of directors whose terms expire at the 2028 annual meeting of stockholders and was not initially assigned to any Board committee. She will be compensated under the company's standard non-employee director program, consisting of cash retainers, restricted stock, and stock option awards.
Key figures
- Committee Assignment
- none initially
- Director Term End Year
- 2028
- Director Election Date
- 2026-08-14
Price after filing
1 day: +2.6%7 days: +4.2%30 days: +4.6%
Close on the filing date to close N calendar days later (from $104.89). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.